Directly Observed Treatment, Short-course (DOTS): A Cornerstone of TB Control

DOTS is a globally recognized strategy for treating tuberculosis, ensuring patients complete their medication to cure the disease and prevent drug resistance.

By Garret Merkley · Explainer · Jul 8, 2026

Branched from Global Efforts to Eradicate Tuberculosis: A Unified Fight Against a Persistent Disease

Quick take

DOTS is a standardized TB treatment strategy where patients take medication under direct supervision.
Its primary goal is to ensure full adherence to medication, curing TB and preventing drug resistance.
The World Health Organization (WHO) introduced DOTS in the 1990s as a highly effective approach.
It involves five key components, from political commitment to consistent drug supply and monitoring.

Directly Observed Treatment, Short-course (DOTS) is a standardized, highly effective strategy for diagnosing and treating tuberculosis (TB). It involves a patient taking their prescribed anti-TB medication under the direct observation of a healthcare worker or a trained community member. This supervision ensures that every dose is taken correctly, which is critical for curing the disease and preventing the development of drug-resistant strains of TB.

How DOTS Works: The Five Pillars of Control

Introduced by the World Health Organization (WHO) in the 1990s, DOTS is built upon five core components designed to create a comprehensive and effective TB control program. These elements work together to address the various challenges of TB treatment, from diagnosis to full recovery.

**Government commitment:** A strong political and financial commitment to sustained TB control activities is foundational, ensuring resources and policies are in place.
**Case detection through quality-assured sputum smear microscopy:** Identifying infectious TB patients is crucial. This involves reliable laboratory services to detect the TB bacteria in a patient's sputum.
**Standardized short-course chemotherapy, directly observed:** This is the heart of DOTS. Patients receive a specific, effective combination of anti-TB drugs for 6-9 months, with each dose observed by a trained individual.
**An effective drug supply and management system:** A consistent, uninterrupted supply of high-quality anti-TB drugs is essential to prevent treatment interruptions and ensure patients complete their regimen.
**A standardized recording and reporting system:** Accurate data collection is vital for monitoring patient progress, evaluating the program's effectiveness, and making informed decisions about TB control efforts.

The Role of Direct Observation

The 'directly observed' part of DOTS is its defining feature and a critical factor in its success. TB treatment is lengthy and involves multiple drugs, which can lead to patients feeling better early on and stopping their medication prematurely. This incomplete treatment is dangerous because it allows the strongest bacteria to survive and multiply, potentially developing resistance to the drugs. By observing each dose, the program ensures full adherence, reduces the risk of treatment failure, and minimizes the emergence of multidrug-resistant TB (MDR-TB). The observer can be a nurse, a community health worker, or a trained family member, depending on the local context and resources.

DOTS profoundly matters because it transformed global TB control. Before DOTS, treatment success rates were often low, and drug resistance was a growing concern. By providing a structured, supervised approach, DOTS significantly improved cure rates, reduced the spread of TB, and prevented millions of deaths. It demonstrated that even in resource-limited settings, effective TB treatment was achievable with proper organization and commitment. While modern TB control has evolved beyond the original DOTS framework to include newer diagnostics and treatments, the core principles of supervised treatment, consistent drug supply, and robust monitoring remain fundamental to successful TB programs worldwide.

Why Direct Observation is Key

Ensures patients take every dose of their medication, even when they start feeling better.
Prevents the development of drug-resistant TB, which is much harder and more expensive to treat.
Provides an opportunity for patients to ask questions and receive support from their observer.
Improves overall treatment success rates and reduces TB transmission within communities.

Is DOTS still the primary strategy for TB control today?

While the core principles of DOTS remain fundamental, global TB control has evolved. The WHO now promotes a broader 'End TB Strategy' which incorporates DOTS principles but also includes newer diagnostics, shorter drug regimens, and expanded patient support, including digital adherence technologies, to further improve outcomes.

Who typically serves as the observer in DOTS?

The observer can vary widely depending on the local healthcare system and patient's circumstances. It could be a nurse, doctor, community health worker, pharmacist, social worker, or even a trained family member or community volunteer. The key is that the observer is trained and trusted.

What happens if a patient misses a dose under DOTS?

Missing doses can compromise treatment effectiveness. Under DOTS, if a dose is missed, the observer or healthcare team would typically follow up with the patient to understand the reason, provide counseling, and reinforce the importance of adherence to prevent further missed doses and ensure treatment completion.

Does DOTS work for all types of TB, including drug-resistant forms?

The original DOTS strategy was designed for drug-susceptible TB. While the principle of direct observation is crucial for all TB treatment, including drug-resistant forms, the specific drug regimens and treatment durations are different and much longer for drug-resistant TB (e.g., MDR-TB or XDR-TB).

What are the main benefits of implementing a DOTS program?

The main benefits include significantly increased treatment success rates, reduced rates of drug resistance, decreased TB transmission in communities, and overall improved public health outcomes. It also provides a structured framework for managing TB cases efficiently.

Sources

World Health Organization (WHO) - Global Tuberculosis Report
World Health Organization (WHO) - Stop TB Strategy and End TB Strategy documents